BCAB
BioAtla, Inc. NASDAQ Listed Dec 16, 2020$4.35
Mkt Cap $5.1M
52w Low $3.92
0.6% of range
52w High $71.50
50d MA $6.83
200d MA $22.78
P/E (TTM)
-0.1x
EV/EBITDA
-0.6x
P/B
—
Debt/Equity
-0.2x
ROE
164.7%
P/FCF
-0.7x
RSI (14)
—
ATR (14)
—
Beta
1.21
50d MA
$6.83
200d MA
$22.78
Avg Volume
47.7K
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
11085 Torreyana Road · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -12.00 | -8.00 | +33.3% | 8.05 | -22.9% | -16.4% | -19.0% | -29.8% | -42.1% | -44.8% | — |
| Nov 13, 2025 | AMC | -0.31 | -0.27 | +12.9% | 32.99 | +6.9% | +19.7% | +54.6% | +84.9% | +75.8% | +75.8% | — |
| Aug 7, 2025 | AMC | -0.29 | -0.31 | -6.9% | 19.00 | -3.7% | -7.2% | -4.6% | -2.6% | +3.3% | -4.2% | — |
| May 6, 2025 | AMC | -0.28 | -0.29 | -3.6% | 23.77 | +0.0% | -5.8% | -0.5% | -9.6% | -9.1% | -7.5% | — |
| Mar 27, 2025 | AMC | -0.40 | -0.32 | +20.0% | 19.63 | -13.4% | -4.9% | -11.7% | -10.0% | -13.5% | -23.6% | — |
| Nov 7, 2024 | AMC | -0.34 | -0.22 | +35.3% | 111.00 | +1.8% | -5.4% | +6.8% | -1.4% | -10.4% | -23.0% | — |
| Aug 8, 2024 | AMC | -0.45 | -0.44 | +2.2% | 73.50 | +2.0% | +0.0% | -5.4% | -4.8% | +14.3% | +27.9% | — |
| May 14, 2024 | AMC | -0.57 | -0.48 | +15.8% | 130.50 | +10.3% | +14.9% | +18.8% | +8.4% | -5.7% | -10.7% | — |
| Mar 26, 2024 | AMC | -0.79 | -0.56 | +29.1% | 150.50 | +1.0% | +15.0% | +14.3% | +12.6% | +16.9% | +22.9% | — |
| Nov 7, 2023 | AMC | -0.77 | -0.70 | +9.1% | 88.00 | +1.7% | -6.2% | -16.8% | -20.7% | -15.9% | -8.5% | — |
| Aug 1, 2023 | AMC | -0.64 | -0.75 | -17.2% | 144.00 | -3.1% | +3.5% | +4.2% | -4.9% | -8.7% | -9.4% | — |
| May 11, 2023 | AMC | -0.66 | -0.58 | +12.1% | 160.50 | +8.7% | +14.3% | +20.6% | +11.2% | +9.3% | +2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $18.51 | $18.38 | -0.7% | +6.0% | -1.7% | -0.6% | +5.0% | +0.0% |
| Mar 31 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $18.67 | $18.50 | -0.9% | -7.1% | -5.4% | -9.1% | -19.7% | -25.0% |
| Mar 31 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $18.67 | $18.50 | -0.9% | -7.1% | -5.4% | -9.1% | -19.7% | -25.0% |
| Nov 13 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $109.50 | $105.00 | -4.1% | -9.1% | -21.9% | -28.8% | -31.1% | -31.5% |
| Sep 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $90.50 | $92.50 | +2.2% | -7.2% | -7.2% | -8.3% | -3.9% | -5.0% |
| May 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $114.00 | $113.50 | -0.4% | -7.9% | -25.0% | -26.3% | -33.3% | -33.3% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $130.50 | $144.00 | +10.3% | +14.9% | +18.8% | +8.4% | -5.7% | -10.7% |
| Mar 28 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $173.00 | $175.00 | +1.2% | -0.6% | -2.0% | +1.7% | +6.9% | +13.3% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $150.50 | $152.00 | +1.0% | +15.0% | +14.3% | +12.6% | +16.9% | +22.9% |
| Dec 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $68.50 | $69.50 | +1.5% | +2.2% | +2.2% | +13.1% | +16.1% | +19.7% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $88.00 | $89.50 | +1.7% | -6.2% | -16.8% | -20.7% | -15.9% | -8.5% |
| Sep 25 | JP Morgan | Maintains | Overweight → Overweight | — | $89.50 | $90.50 | +1.1% | -3.9% | -2.2% | +1.7% | +0.0% | -5.0% |
| Aug 2 | EF Hutton | Maintains | Buy → Buy | — | $144.00 | $139.50 | -3.1% | +3.5% | +4.2% | -4.9% | -8.7% | -9.4% |
| Aug 2 | JP Morgan | Maintains | Overweight → Overweight | — | $144.00 | $139.50 | -3.1% | +3.5% | +4.2% | -4.9% | -8.7% | -9.4% |
| Aug 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $144.00 | $139.50 | -3.1% | +3.5% | +4.2% | -4.9% | -8.7% | -9.4% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $144.00 | $139.50 | -3.1% | +3.5% | +4.2% | -4.9% | -8.7% | -9.4% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $183.50 | $185.00 | +0.8% | +5.4% | -2.7% | -4.4% | -10.4% | -8.7% |
| May 15 | JMP Securities | Maintains | Outperform → Outperform | — | $183.50 | $185.00 | +0.8% | +5.4% | -2.7% | -4.4% | -10.4% | -8.7% |
| May 12 | EF Hutton | Maintains | Buy → Buy | — | $160.50 | $174.50 | +8.7% | +14.3% | +20.6% | +11.2% | +9.3% | +2.5% |
| Apr 17 | EF Hutton | Maintains | Buy → Buy | — | $180.00 | $181.50 | +0.8% | +6.1% | +5.0% | +0.8% | -2.8% | -3.6% |
| Apr 3 | JP Morgan | Maintains | Overweight → Overweight | — | $134.00 | $137.00 | +2.2% | +5.6% | +5.6% | +12.3% | +24.6% | +29.1% |
| Mar 28 | BTIG | Maintains | Buy → Buy | — | $124.50 | $125.00 | +0.4% | -5.6% | +0.8% | -1.2% | +7.6% | +13.7% |
| Mar 27 | JMP Securities | Maintains | Outperform → Outperform | — | $118.00 | $118.50 | +0.4% | +5.5% | -0.4% | +6.4% | +4.2% | +13.6% |
| Mar 24 | Credit Suisse | Maintains | Neutral → Neutral | — | $115.00 | $116.50 | +1.3% | +2.6% | +8.3% | +2.2% | +9.1% | +7.0% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $115.00 | $116.50 | +1.3% | +2.6% | +8.3% | +2.2% | +9.1% | +7.0% |
| Jan 5 | EF Hutton | Maintains | Buy → Buy | — | $403.50 | $415.00 | +2.9% | +2.2% | +2.0% | -4.3% | -48.6% | -54.2% |
| Nov 4 | Credit Suisse | Maintains | Neutral → Neutral | — | $318.00 | $403.50 | +26.9% | +18.7% | +26.9% | +24.5% | +24.4% | +28.0% |
| Sep 15 | JMP Securities | Maintains | Market Outperform → Outperform | — | $448.00 | $459.50 | +2.6% | -4.6% | -6.5% | -7.0% | -6.4% | -3.1% |
| Aug 10 | Credit Suisse | Maintains | Neutral → Neutral | — | $180.50 | $203.00 | +12.5% | +83.1% | +120.2% | +93.6% | +121.6% | +228.8% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $180.50 | $203.00 | +12.5% | +83.1% | +120.2% | +93.6% | +121.6% | +228.8% |
| May 5 | Credit Suisse | Downgrade | Outperform → Neutral | — | $204.00 | $168.00 | -17.6% | -41.2% | -46.6% | -47.3% | -42.2% | -46.8% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $288.50 | $300.50 | +4.2% | -5.4% | -0.2% | -10.6% | -13.7% | -22.5% |
| Jun 28 | Roth Capital | Maintains | Buy → Buy | — | $2137.50 | $2168.00 | +1.4% | +2.1% | +6.3% | -0.9% | +2.3% | +2.1% |
| Mar 26 | BTIG | Maintains | Buy → Buy | — | $3036.50 | $3038.00 | +0.0% | -5.5% | -14.0% | -17.1% | -16.3% | -15.9% |
| Jan 11 | JP Morgan | Maintains | Overweight → Overweight | — | $1912.50 | $1879.00 | -1.8% | +5.1% | +6.8% | +17.2% | +21.6% | +18.6% |
| Jan 11 | Jefferies | Maintains | Buy → Buy | — | $1912.50 | $1879.00 | -1.8% | +5.1% | +6.8% | +17.2% | +21.6% | +18.6% |
| Jan 11 | Credit Suisse | Maintains | Outperform → Outperform | — | $1912.50 | $1879.00 | -1.8% | +5.1% | +6.8% | +17.2% | +21.6% | +18.6% |
| Jan 11 | BTIG | Maintains | Buy → Buy | — | $1912.50 | $1879.00 | -1.8% | +5.1% | +6.8% | +17.2% | +21.6% | +18.6% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
BCAB completed a merger with BA Merger Sub on April 2, 2026, fundamentally altering the company's ownership structure and potentially its strategic direction, which investors need to monitor for governance changes and operational implications.
Apr 2
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
BCAB disclosed material information via Regulation FD that won't be incorporated into future SEC filings, limiting its legal binding effect and suggesting the company is being cautious about liability from the disclosed information.
Mar 31
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The company is implementing retention bonuses for executives, signaling leadership stability concerns and potential execution risks that could impact investor confidence and stock performance.
Mar 23
8-K · 5.02
!!! Very High
BioAtla, Inc. -- 8-K 5.02: Executive Change
BioAtla (BCAB) appointed Richard Waldron and Chris Vasquez as Vice Presidents while Waldron resigned from the board, indicating internal leadership restructuring without major strategic implications.
Mar 2
8-K
BioAtla, Inc. -- 8-K Filing
BioAtla faces potential Nasdaq delisting after failing to maintain the required $35 million minimum market value for 69 consecutive trading days, with disputes over compliance determination and voting stock policies.
Feb 9
8-K · 7.01
! Medium
BioAtla, Inc. -- 8-K 7.01: Regulation FD Disclosure
BioAtla secured $30 million in prepaid advances and a standby equity purchase agreement with Yorkville and Anson funds, providing capital flexibility for operations.
Feb 6
Data updated apr 24, 2026 8:48pm
· Source: massive.com